Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
Aldosterone responsiveness to consecutive i.v. injections of metoclopramide 1 mg, 2.5 mg and 10 mg was studied in 8 patients with prolactinoma and normally preserved adrenal function and in 14 healthy volunteers. In the patients, aldosterone response to metoclopramide 1 mg was blunted. After metoclopramide 10 mg, aldosterone rose to the same levels in patients and volunteers. In the patients, however, percentage rise of aldosterone was enhanced, since the appropriate base line concentration of aldosterone was decreased. Thus, there is evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
D000328:Adult; D000450:Aldosterone / Q000378:metabolism*; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*
D000450:Aldosterone; D011388:Prolactin; D008787:Metoclopramide; D004298:Dopamine